Recent Updates
Recently added Catalysts
NTHI Positive Sentiment

NeOnc Technologies: The Future of Neurosurgery | New Frontiers

Key Takeaway: NeOnc Technologies is revolutionizing neurosurgery with a non-invasive intranasal drug delivery system aimed at treating aggressive brain cancers. Founded by Dr. Thomas Chen, the company focuses on therapies like NEO100 and NEO212, which target glioblastoma multiforme while minimizing side effects. The upcoming documentary will highlight these advancements and their impact on patient care, set to air in 2025.

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a non-invasive drug delivery system for brain cancer.
  • Potential to improve survival rates and reduce side effects.
  • Commitment to ethical research and patient-centered care.
  • Innovative therapies like NEO100 and NEO212 show promise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Perillyl alcohol
Phase 1 · Glioblastoma Multiforme

Full Press Release Details

In a gripping new episode of New Frontiers by Planet TV Studios, viewers are taken inside the revolutionary world of NeOnc Technologies Holdings, Inc. , a biotech company redefining the battle against aggressive brain cancers. At the heart of this transformation is Dr. Thomas Chen , Director of Surgical Neuro-Oncology at USC and NeOnc’s founder. The episode showcases how Dr. Chen’s lifelong mission to help patients with brain cancer has led to the development of a non-invasive intranasal drug delivery system that bypasses the blood-brain barrier (BBB)—a breakthrough that could change the future of neuro-oncology forever.
Hosted by Gina Grad , the episode highlights the science and humanity driving NeOnc’s efforts. Through engaging interviews and on-the-ground reporting, New Frontiers> explores how NeOnc’s therapies—particularly NEO100 , a purified form of perillyl alcohol, and NEO212 , a novel drug combining perillyl alcohol with TMZ—offer precise, targeted treatments for patients suffering from deadly conditions like glioblastoma multiforme. These patented therapies are designed not only to improve survival rates but also to minimize the harsh side effects typically associated with brain cancer treatments.
The documentary delves into how intranasal drug delivery is becoming a game-changing method for reaching the brain without surgery, IVs, or hospital stays. By leveraging the body’s own cranial nerve pathways, NeOnc’s platform allows cancer-fighting compounds to reach their targets efficiently, safely, and often from the comfort of the patient’s home. This segment also gives viewers a glimpse into the real-world impact of these advancements, featuring testimonies from patients who have experienced extended survival and improved quality of life.
In addition to its scientific breakthroughs, the episode spotlights NeOnc’s commitment to ethical research and patient-centered care . Dr. Chen’s team combines rigorous clinical methodology with a deep understanding of patient needs, ushering in a new era of personalized medicine and minimally invasive neurosurgery . These values are particularly critical as the company prepares for its direct listing on Nasdaq in Q1 2025 , signaling a new phase of growth and visibility in the biotech sector.
Set to air nationwide in Q2/Q3 2025 , New Frontiers: The Future of Neurosurgery will also be available on-demand across Amazon, YouTube, Vimeo, Facebook, and Roku , making this extraordinary story accessible to a global audience. With the spotlight on NeOnc’s innovations, this episode presents a compelling vision of what happens when world-class science meets compassion, ingenuity, and hope.

Frequently Asked Questions

What is NeOnc Technologies known for?

NeOnc Technologies is known for developing innovative therapies for aggressive brain cancers.

What are NEO100 and NEO212?

NEO100 is a purified form of perillyl alcohol, while NEO212 combines perillyl alcohol with TMZ.

How does the intranasal drug delivery system work?

It utilizes cranial nerve pathways to deliver cancer-fighting compounds directly to the brain.

When will the documentary air?

The documentary is set to air nationwide in Q2/Q3 2025.

What is the significance of NeOnc's Nasdaq listing?

The direct listing on Nasdaq in Q1 2025 marks a new phase of growth and visibility for NeOnc.

Last updated: Feb 11, 2025